DS
David R Strayer
Chief Science/Medical Officer

David R Strayer insider trades: Hemispherx Biopharma (HEB) stock buys and sales

Chief Science/Medical Officer, Hemispherx Biopharma Last trade Jun 21, 2019 34 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
8
Open-market trades
since 2008
1
Company
last trade 2019

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where David reports to the SEC

Open-market buys and sales

8 trades reported on SEC Form 4, newest first

DateStockTypeValue
Jun 21, 2019HEB↑ Buy$10K
May 2, 2017HEB↑ Buy$5K
Feb 16, 2017HEB↑ Buy$5K
May 18, 2012HEB↑ Buy$13K
Jun 23, 2010HEB↓ Sell$28K
Jun 16, 2010HEB↑ Buy$133K
Dec 7, 2009HEB↑ Buy$7K
Sep 25, 2008HEB↑ Buy$10K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About David R Strayer's insider trades

David R Strayer is Chief Science/Medical Officer at Hemispherx Biopharma (HEB). Since Sep 25, 2008, David has reported 7 open-market purchases worth $182K and 1 sale worth $28K on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include grants and awards (22 filings), other transactions (2 filings), conversions (1 filing), option exercises (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every HEB insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.